Trials
1 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The purpose of this Phase 3, non-randomized, single-arm, open-label study is to evaluate the immune response, reactogenicity and safety of GSKs dTpa vaccine in Japanese pregnant women between 27 weeks and less than 37 weeks of pregnancy. Both the pregnant women and their neonates born during the study will be evaluated for specific analyses.”In the company’s words, NCT07596199 on ClinicalTrials.gov
- Other names
- Boostrix
Other drugs for Diphtheria-Tetanus-acellular Pertussis Vaccines
- LBVDLG Chem · Phase 2/3
- BK1803Tanabe Pharma Corporation · Phase 3
- DiphtheriaChina National Biotec Group Company Limited · Phase 3
- DTcPCanSino Biologics Inc. · Phase 3
- Tdap vaccineChangchun BCHT Biotechnology Co. · Phase 2
- Batch 1 ofCanSino Biologics Inc. · Phase 1
Coming up1
- 23 NovPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 23 Nov 2026 | A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women | |
| Phase 3Completed | 4 Sep 2026 | A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Healthy Japanese Adolescents Aged 11 Years to <13 Years |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026